Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
US2025171502A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025171502-A1 |
| Application number | US-202418946551-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 13, 2024 |
| Priority date | Jul 13, 2018 |
| Publication date | May 29, 2025 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embodiments herein report compositions, methods, uses and manufacturing procedures for rotavirus constructs and immunogenic compositions thereof. Some embodiments concern compositions that include, but are not limited to, chimeric rotaviruses of use in immunogenic compositions against rotavirus infection as well as against other pathogenic virus infection in a subject. In certain embodiments, constructs of use herein can be generated and used where a rotavirus expression system further includes one or more nucleic acid molecules encoding one or more polypeptides of another pathogen (e.g. another enteric or mucosal pathogen).
Opening claim text (preview).
What is claimed is: 1 . A recombinant rotavirus comprising: a gene segment including a nucleotide sequence encoding at least one nucleotide sequence selected from the group consisting of: rotavirus nonstructural protein 1 (NSP1), rotavirus nonstructural protein 3 (NSP3), rotavirus nonstructural protein 5 (NSP5); and a nucleotide sequence encoding a non rotavirus polypeptide, wherein the (i) NSP1, NSP3, or NSP5 and (ii) the non-rotavirus polypeptide are encoded by a single open reading frame, separated by a self-cleavage protease domain. 2 . The recombinant rotavirus of claim 1 , wherein the self-cleavage protease domain is a 2A cleavage element. 3 . The recombinant rotavirus of claim 1 , wherein the self-cleavage protease domain is a tesco porcine virus 2A (P2A) element. 4 . The recombinant rotavirus of claim 3 , wherein the P2A element has a sequence having at least 80% sequence identity to SEQ ID NO: 1 (S KF QID KILIS GDIELNPGP). 5 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is derived from a virus that causes gastroenteritis. 6 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is derived from a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, enterovirus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picornavirus, and coronavirus. 7 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide induces an immunological response against a second virus that is not rotavirus. 8 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide induces an immunological response against a virus selected from the group consisting of: norovirus, enterovirus, poliovirus, coxsackie virus, enterovirus, hepatitis A virus, hepatitis C virus, hepatitis E virus, calicivirus, astrovirus, parechovirus, reovirus, adenovirus, torovirus, picomavirus, and coronavirus. 9 . The recombinant rotavirus of claim 1 , wherein the non-rotavirus polypeptide is selected from the group consisting of norovirus VP1 protein, noro virus P domain, and norovirus P2 domain. 10 . The recombinant rotavirus of claim 1 , wherein the recombinant rotavirus is based upon strain GIP. 11 . The recombinant rotavirus of claim 1 , wherein the recombinant rotavirus is attenuated.
Methods of production or purification of viral material · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.